270 related articles for article (PubMed ID: 37497384)
1. Dopamine agonists in Parkinson's disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment.
Isaacson SH; Hauser RA; Pahwa R; Gray D; Duvvuri S
Clin Park Relat Disord; 2023; 9():100212. PubMed ID: 37497384
[TBL] [Abstract][Full Text] [Related]
2. Rationale and Development of Tavapadon, a D1/D5-Selective Partial Dopamine Agonist for the Treatment of Parkinson's Disease.
Bezard E; Gray D; Kozak R; Leoni M; Combs C; Duvvuri S
CNS Neurol Disord Drug Targets; 2024; 23(4):476-487. PubMed ID: 36999711
[TBL] [Abstract][Full Text] [Related]
3. Pergolide : A Review of its Pharmacology and Therapeutic Use in Parkinson's Disease.
Markham A; Benfield P
CNS Drugs; 1997 Apr; 7(4):328-40. PubMed ID: 27520755
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of D2 and D3 dopamine receptor selective compounds on L-dopa-dependent abnormal involuntary movements in rats.
Kumar R; Riddle LR; Griffin SA; Chu W; Vangveravong S; Neisewander J; Mach RH; Luedtke RR
Neuropharmacology; 2009; 56(6-7):956-69. PubMed ID: 19371586
[TBL] [Abstract][Full Text] [Related]
5. Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's disease.
Jenner P
Curr Opin Neurol; 2003 Dec; 16 Suppl 1():S3-7. PubMed ID: 15180131
[TBL] [Abstract][Full Text] [Related]
6. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
Blanchet PJ; Konitsiotis S; Chase TN
J Pharmacol Exp Ther; 1997 Nov; 283(2):794-9. PubMed ID: 9353400
[TBL] [Abstract][Full Text] [Related]
7. D
Mailman RB; Yang Y; Huang X
Eur J Pharmacol; 2021 Feb; 892():173760. PubMed ID: 33279520
[TBL] [Abstract][Full Text] [Related]
8. Targeting the dopamine D3 receptor: an overview of drug design strategies.
Cortés A; Moreno E; Rodríguez-Ruiz M; Canela EI; Casadó V
Expert Opin Drug Discov; 2016 Jul; 11(7):641-64. PubMed ID: 27135354
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of 50-kHz ultrasonic vocalizations by dopamine receptor subtype-selective agonists and antagonists in adult rats.
Scardochio T; Clarke PB
Psychopharmacology (Berl); 2013 Apr; 226(3):589-600. PubMed ID: 23192317
[TBL] [Abstract][Full Text] [Related]
10. Dopamine receptors--physiological understanding to therapeutic intervention potential.
Emilien G; Maloteaux JM; Geurts M; Hoogenberg K; Cragg S
Pharmacol Ther; 1999 Nov; 84(2):133-56. PubMed ID: 10596903
[TBL] [Abstract][Full Text] [Related]
11. Pre-clinical studies of pramipexole: clinical relevance.
Hubble JP
Eur J Neurol; 2000 May; 7 Suppl 1():15-20. PubMed ID: 11054154
[TBL] [Abstract][Full Text] [Related]
12. Characterization of unconditioned behavioral effects of dopamine D3/D2 receptor agonists.
Geter-Douglass B; Katz JL; Alling K; Acri JB; Witkin JM
J Pharmacol Exp Ther; 1997 Oct; 283(1):7-15. PubMed ID: 9336302
[TBL] [Abstract][Full Text] [Related]
13. Discriminative stimulus effects of putative D3 dopamine receptor agonists in rats.
Katz JL; Alling KL
Behav Pharmacol; 2000 Sep; 11(6):483-93. PubMed ID: 11103914
[TBL] [Abstract][Full Text] [Related]
14. The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease.
Frau R; Savoia P; Fanni S; Fiorentini C; Fidalgo C; Tronci E; Stancampiano R; Meloni M; Cannas A; Marrosu F; Bortolato M; Devoto P; Missale C; Carta M
Exp Neurol; 2017 May; 291():1-7. PubMed ID: 28131725
[TBL] [Abstract][Full Text] [Related]
15. Dopamine agonists used in the treatment of Parkinson's disease and their selectivity for the D1, D2, and D3 dopamine receptors in human striatum.
De Keyser J; De Backer JP; Wilczak N; Herroelen L
Prog Neuropsychopharmacol Biol Psychiatry; 1995 Nov; 19(7):1147-54. PubMed ID: 8787038
[TBL] [Abstract][Full Text] [Related]
16. Mapping the effects of three dopamine agonists with different dyskinetogenic potential and receptor selectivity using pharmacological functional magnetic resonance imaging.
Delfino M; Kalisch R; Czisch M; Larramendy C; Ricatti J; Taravini IR; Trenkwalder C; Murer MG; Auer DP; Gershanik OS
Neuropsychopharmacology; 2007 Sep; 32(9):1911-21. PubMed ID: 17287822
[TBL] [Abstract][Full Text] [Related]
17. The rationale for the use of dopamine agonists in Parkinson's disease.
Jenner P
Neurology; 1995 Mar; 45(3 Suppl 3):S6-12. PubMed ID: 7715795
[TBL] [Abstract][Full Text] [Related]
18. Endogenous dopaminergic tone and dopamine agonist action.
Treseder SA; Smith LA; Jenner P
Mov Disord; 2000 Sep; 15(5):804-12. PubMed ID: 11009183
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson's disease.
Utsumi H; Okuma Y; Kano O; Suzuki Y; Iijima M; Tomimitsu H; Hashida H; Kubo S; Suzuki M; Nanri K; Matsumura M; Murakami H; Hattori N;
Intern Med; 2013; 52(3):325-32. PubMed ID: 23370739
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
